Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 15;17(9):e0273183.
doi: 10.1371/journal.pone.0273183. eCollection 2022.

Proximal tubular renal dysfunction among HIV infected patients on Tenofovir versus Tenofovir sparing regimen in western Kenya

Mercy Jelagat Karoney  1 , Mathew Kirtptonui Koech  1 , Evangeline Wawira Njiru  1 , Willis Dixon Owino Ong'or  1
Affiliations

Proximal tubular renal dysfunction among HIV infected patients on Tenofovir versus Tenofovir sparing regimen in western Kenya

Mercy Jelagat Karoney et al. PLoS One. .

Abstract

Introduction: Tenofovir Disoproxil Fumarate (TDF) is the most widely used Anti-Retroviral Therapy (ART) drug due to its potency, safety profile and World Health Organization (WHO) recommendation. TDF causes proximal tubular renal dysfunction (PTRD) leading to Fanconi syndrome, acute kidney injury and chronic kidney disease. Modest rates (2-4%) of TDF related toxicity based on estimated Glomerular Filtration Rate (GFR) have been described, while TDF-induced PTRD has been reported to be 22%. TDF toxicity is more likely among African patients, it is reversible and TDF may be renal dosed in patients with dysfunction. The objective of this study was to assess proximal tubular renal dysfunction, global renal function, and their determinants among patients on TDF versus TDF-sparing regimen.

Methods: This was a cross-sectional study among people living with HIV/AIDS (PLWHA) attending the Academic Model Providing Access to Healthcare (AMPATH) program. The primary outcome of interest in this study was PTRD while the secondary outcome of interest was estimated GFR. PTRD was defined as any two of beta-2 microglobulin in urine, metabolic acidosis, normoglycemic glucosuria and fractional excretion of phosphate. Student's t-test, chi-square and their non-parametric equivalents were used to test for statistical significance. Univariate and multivariate logistic regression analysis was carried out.

Results: A total of 516 participants were included in the final analysis, 261 on TDF while 255 were on TDF-sparing regimens. The mean (SD) age of all participants was 41.5 (12.6) years with majority being female (60.3%). The proportion of PTRD was 10.0% versus 3.1% in the TDF compared to TDF-sparing group (P<0.001). Mean estimated GFR was 112.8 (21.5) vs 109.7 (21.9) ml/min/1.73mm3 (P = 0.20) for the TDF compared to TDF-sparing group. TDF users were more likely to have PTRD compared to non-TDF users, adjusted Odds Ratio (AOR) 3.0, 95% CI 1.12 to 7.75.

Conclusion: There was significant PTRD in the TDF compared to TDF-sparing group without significant difference in estimated GFR. The clinical significance of these findings may not be clear in the short term.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Recruitment schema.
Fig 2
Fig 2. Percentage of participants with abnormal renal parameters for the overall group as well as categorized by TDF use.
See this image and copyright information in PMC

References

    1. Röling J, Schmid H, Fischereder M, Draenert R, Goebel FD: HIV-Associated Renal Diseases and Highly Active Antiretroviral Therapy—Induced Nephropathy. Clinical Infectious Diseases 2006, 42(10):1488–1495. - PubMed
    1. Lacey MJ: Impact of Pharmaceutical Innovation in HIV/AIDS Treatment During the Highly Active Antiretroviral Therapy (HAART) Era in the US, 1987–2010. 2014.
    1. Szczech LA, Gupta SK, Habash R, Guasch A, Kalayjian R, Appel R, et al. : The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. Kidney international 2004, 66(3):1145–1152. - PubMed
    1. Kalyesubula R, Perazella MA: Nephrotoxicity of HAART. AIDS Research and Treatment 2011, 2011. - PMC - PubMed
    1. Post FA, Wyatt CM, Mocroft A: Biomarkers of impaired renal function. Current opinion in HIV and AIDS 2010, 5(6):524–530. - PubMed

Publication types